Latest Period
Q1 2026
Security Snapshot
PALVELLA THERAPEUTICS, INC. - Common Stock, $0.01 par value (PVLA) Institutional Ownership
CUSIP: 697947109
13F Institutional Holders and Ownership History from Q4 2024 to Q1 2026
Institutions Reporting
179
Shares (Excl. Options)
13,189,589
Price
$124.65
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, $0.01 par value
- Symbol
- PVLA on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 13,189,589
- Total 13F value
- $1,638,163,573
- Portfolio coverage rank
- 0.01%
- Share change
- +3,313,386
- Value change
- +$428,700,014
- Number of holders
- 179
- Shares outstanding
- 11,842,870
- SEC-reported price per share
- $120.57
- Insider filing price
- $120.57
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- PVLA - PALVELLA THERAPEUTICS, INC. - Common Stock, $0.01 par value is tracked under CUSIP 697947109.
- 179 institutions reported positions in Q1 2026.
- 7 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 141 to 179 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $1,021,544,191 to $1,638,163,573.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 179 institutions filings for Q1 2026.
Security key
697947109
Latest holder period
Q1 2026
13F holders
179
13D/G owners
7
CIK / CUSIP context first
Open Q1 2026 holders
PVLA full holder history
PALVELLA THERAPEUTICS, INC. SEC filings
PALVELLA THERAPEUTICS, INC. company facts
PALVELLA THERAPEUTICS, INC. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 697947109:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
7
Security
PVLA
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Kaupinen Wes | 15% | $38,555,729 | 1,644,869 | Kaupinen Wes | 13 Dec 2024 | |||
| First Light Asset Management, LLC | 7.5% | $89,137,745 | 887,031 | First Light Asset Management, LLC | 31 Dec 2025 | |||
| BIOTECHNOLOGY VALUE FUND L P | 7.1% | -29% | $88,331,614 | -$30,366,571 | 879,009 | -26% | BVF PARTNERS L P/IL | 31 Dec 2025 |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 7.4% | -13% | $51,556,256 | +$6,766,571 | 822,400 | +15% | SUVRETTA CAPITAL MANAGEMENT, LLC | 30 Sep 2025 |
| Frazier Life Sciences Public Fund, L.P. | 6% | +22% | $70,982,116 | +$16,164,419 | 706,360 | +29% | Frazier Life Sciences Public Fund, L.P. | 31 Dec 2025 |
| Samsara BioCapital, L.P. | 3.1% | -50% | $8,989,600 | -$8,989,600 | 339,743 | -50% | Samsara BioCapital, L.P. | 30 Jun 2025 |
| Dellora Investments LP | 1.3% | $3,306,892 | 141,079 | Dellora Investments LP | 13 Dec 2024 |
As of 31 Mar 2026, 179 institutional investors reported holding 13,189,589 shares of PALVELLA THERAPEUTICS, INC. - Common Stock, $0.01 par value (PVLA). This represents 111% of the company’s total 11,842,870 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
87%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| SUVRETTA CAPITAL MANAGEMENT, LLC | 9.7% | 1,153,496 | +29% | 3.9% | $143,783,276 |
| First Light Asset Management, LLC | 8.3% | 980,758 | +38% | 11% | $122,251,485 |
| BVF INC/IL | 8.1% | 960,989 | +9.3% | 3.8% | $119,787,279 |
| Frazier Life Sciences Management, L.P. | 7.5% | 882,400 | +22% | 2.8% | $109,991,160 |
| BlackRock, Inc. | 5.8% | 686,853 | +23% | 0% | $85,616,227 |
| JENNISON ASSOCIATES LLC | 5.4% | 640,611 | +65% | 0.05% | $79,852,163 |
| VANGUARD CAPITAL MANAGEMENT LLC | 4% | 477,294 | 0% | 0% | $59,494,697 |
| STATE STREET CORP | 3.9% | 458,999 | +9.2% | 0% | $57,214,225 |
| FEDERATED HERMES, INC. | 3.7% | 433,015 | +18% | 0.09% | $53,975,320 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 3.4% | 402,564 | +9743% | 0.01% | $50,180,000 |
| FRONTIER CAPITAL MANAGEMENT CO LLC | 3.2% | 374,035 | 0.48% | $46,623,461 | |
| Woodline Partners LP | 2.7% | 317,517 | +5.7% | 0.15% | $39,578,494 |
| ALLIANCEBERNSTEIN L.P. | 2.2% | 262,835 | -2.3% | 0.01% | $27,510,939 |
| Siren, L.L.C. | 2.2% | 257,485 | +243% | 0.89% | $32,095,505 |
| EVENTIDE ASSET MANAGEMENT, LLC | 2% | 233,248 | +129% | 0.48% | $29,049,685 |
| FMR LLC | 1.8% | 215,808 | -6.9% | 0% | $26,900,498 |
| MPM BIOIMPACT LLC | 1.7% | 206,404 | +0.32% | 2% | $25,728,259 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.7% | 205,609 | +15% | 0% | $25,636,522 |
| PRIMECAP MANAGEMENT CO/CA/ | 1.6% | 195,030 | 0.02% | $24,310,490 | |
| GOLDMAN SACHS GROUP INC | 1.6% | 194,179 | +96% | 0% | $24,204,412 |
| Artisan Partners Limited Partnership | 1.6% | 193,796 | -8.4% | 0.04% | $24,156,671 |
| Alyeska Investment Group, L.P. | 1.5% | 179,922 | 0.06% | $22,427,277 | |
| EMERALD ADVISERS, LLC | 1.4% | 161,500 | 0.64% | $20,130,975 | |
| First Turn Management, LLC | 1.3% | 148,093 | 2.1% | $18,459,792 | |
| ORBIMED ADVISORS LLC | 1.1% | 134,600 | 0.38% | $16,777,890 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
6
Latest
Q1 2026
Rows shown
1-6 of 6
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 13,189,589 | $1,638,163,573 | +$428,700,014 | $124.65 | 179 |
| 2025 Q4 | 9,759,838 | $1,021,544,191 | +$142,062,451 | $104.67 | 141 |
| 2025 Q3 | 8,525,488 | $534,466,075 | +$183,107,977 | $62.69 | 100 |
| 2025 Q2 | 5,909,706 | $133,205,244 | +$16,635,084 | $22.54 | 64 |
| 2025 Q1 | 5,123,397 | $143,404,590 | +$33,701,617 | $27.99 | 40 |
| 2024 Q4 | 4,033,052 | $48,417,227 | +$48,417,227 | $12.00 | 32 |